Shots:
The companies collaborated to remove Gal-3 from blood plasma for AKI & S-AKI and will initially conduct studies on large animals with an expected initiation in 2022, followed by human trials. ETI plans to report the results from the human clinical trial in ~3yrs.
The collaboration will use Terumo’s spectra optia apheresis system in large animal & human trials with ETI’s XGal-3 column, initially tested in AKI & S-AKI that are designed to selectively remove Gal-3 from blood plasma
The XGal-3 column device is intended to enhance health outcomes for critically ill patients, decrease the incidence of CKD & hospital mortality to decrease the need for dialysis & shorten stays in intensive care
Ref: GlobalNewswire | Image: Eliaz Therapeutics
